Provided by Tiger Trade Technology Pte. Ltd.

Zentalis Pharmaceuticals, LLC

3.76
-0.0650-1.70%
Post-market: 3.760.00000.00%16:49 EDT
Volume:988.29K
Turnover:3.78M
Market Cap:355.97M
PE:-1.92
High:3.96
Open:3.84
Low:3.75
Close:3.83
52wk High:6.95
52wk Low:1.21
Shares:94.67M
Float Shares:76.90M
Volume Ratio:0.72
T/O Rate:1.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9591
EPS(LYR):-1.9100
ROE:-66.75%
ROA:-33.15%
PB:2.48
PE(LYR):-1.97

Loading ...

Walters Group Reports Purchase of 4,335,000 Zentalis Shares for $15.17 Million

Reuters
·
Aug 20

Zentalis Pharmaceuticals Closes Offering of Common Shares

MT Newswires Live
·
Aug 18

Zentalis Closes 26,450,000-Share Public Offering at $3.5 Per Share, Raises $92.6 Million Gross

Reuters
·
Aug 18

Sector Update: Healthcare

MT Newswires Live
·
Aug 15

U.S. Stocks on the MOVE-Reddit, Capricor Therapeutics, Birkenstock

Reuters
·
Aug 14

Zentalis Pharmaceuticals Prices $80.5 Million Offering to Fund Clinical Pipeline

MT Newswires Live
·
Aug 14

Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering

Reuters
·
Aug 14

Zentalis Prices 23 Million-Share Follow-on Offering at $3.5 Per Share

Reuters
·
Aug 14

Zentalis Pharmaceuticals - Prices Public Offering of 23 Mln Shares at $3.50 Per Share

THOMSON REUTERS
·
Aug 14

Zentalis Pharma Falls After Starting Stock Offering

Reuters
·
Aug 14

Zentalis Pharmaceuticals Launches Underwritten Public Offering of Common Stock, Pre-Funded Warrants

Reuters
·
Aug 14

Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering

THOMSON REUTERS
·
Aug 14

Zentalis price target raised to $5 from $4 at Morgan Stanley

TIPRANKS
·
Aug 07

Gyre Therapeutics Q2 Revenue Beats Estimates on Higher Etuary Sales Volumes

Reuters
·
Aug 07

Morgan Stanley Adjusts PT on Zentalis Pharmaceuticals to $5 From $4, Maintains Equalweight Rating

MT Newswires Live
·
Aug 07

Zentalis Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Aug 07

Zentalis Pharmaceuticals Q2 EPS USD -0.59

THOMSON REUTERS
·
Aug 07

Zentalis Says Denali Phase 2 Topline Data for Azenosertib Expected in 1H 2027

Reuters
·
Aug 07

Zentalis Grants 84,000 Inducement Stock Options at $4.65 Per Share

Reuters
·
Aug 04

Zentalis Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 04